Heart Disease & Cardiology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

This large Phase 3 trial is studying inclisiran, a newer injection designed to lower cholesterol in people with atherosclerotic cardiovascular disease. If inclisiran proves effective, it may reduce the risk of heart attacks and strokes by offering a simpler way to manage cholesterol levels. The study is actively enrolling over 16,000 participants in the US and UK, which could help bring this treatment option to many patients in the future.

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

This Phase 3 trial is testing a new drug called omecamtiv mecarbil in patients with severe heart failure symptoms and very low heart pumping function. The goal is to see if this medication can reduce the chance of serious problems like hospital stays, heart transplants, or death. With recruitment ongoing in the US and Europe, this study may lead to an additional treatment option for people living with difficult-to-manage heart failure.

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

This global Phase 3 trial is investigating a new injectable drug, NNC0487-0111, for adults who have both heart failure and obesity. If successful, the treatment could help lower the risk of heart complications and reduce hospital visits related to heart failure. The study focuses on patients with specific types of heart failure and excess body weight, aiming to address the unique challenges faced by this group.

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

This Phase 4 study compares using aspirin alone against aspirin combined with fondaparinux in people who have had a certain type of heart attack called Non-ST-elevation Myocardial Infarction (NSTEMI). The trial aims to find out if aspirin by itself is just as effective while possibly reducing the risk of bleeding before early heart procedures. About 5,000 patients in Denmark are being enrolled to help clarify the best treatment approach during this critical period.

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old

This Phase 4 study focuses on young people under 21 who develop myocarditis or pericarditis, which are types of heart inflammation, after receiving the COMIRNATY COVID-19 vaccine. The research aims to understand the long-term effects on the heart following vaccination and compare them to heart inflammation caused by COVID-19 infection itself. With up to 319 participants being followed in the US over five years, this study will provide important information on vaccine safety in this age group.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.